These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 34181768)

  • 21. Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients.
    Martinez S; Sindu D; Nailor MD; Cherrier L; Tokman S; Walia R; Goodlet KJ
    Transpl Infect Dis; 2024 Jun; 26(3):e14279. PubMed ID: 38742601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
    Saltiel G; Faure E; Assaf A; Chopin MC; Moreau F; Faure K; Goeminne C; Vuotto F
    Clin Transplant; 2024 May; 38(5):e15327. PubMed ID: 38686437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis.
    Wong DD; van Zuylen WJ; Novos T; Stocker S; Reuter SE; Au J; Foster CSP; Day RO; Horvath AR; Endre Z; Rawlinson WD
    Microbiol Spectr; 2022 Jun; 10(3):e0268421. PubMed ID: 35658598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease.
    Fayek SA; Beshears E; Lieber R; Alvey N; Sauer A; Poirier J; Hollinger EF; Olaitan OK; Jensik S; Geyston J; Brokhof MM; Hodowanec AC; Hertl M; Simon DM
    Transplant Proc; 2016; 48(6):2056-2064.e1. PubMed ID: 27569944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resource Use and Financial Impact of Oral Step-Down Therapy for Resistant Cytomegalovirus in Solid Organ Transplant Recipients.
    Kleiboeker H; Descourouez JL; Schulz LT; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA; Jorgenson MR
    Transplant Proc; 2024 Mar; 56(2):434-439. PubMed ID: 38355369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Novelties for the management of cytomegalovirus after kidney transplantation].
    Kamar N; Marion O; Del Bello A
    Nephrol Ther; 2024 Aug; 20(4):269-276. PubMed ID: 39129511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Five-year single-center analysis of cytomegalovirus viremia in kidney transplant recipients and possible implication for novel prophylactic therapy approaches.
    Trappe M; Affeldt P; Grundmann F; Kann M; Koehler FC; Müller RU; Stippel D; Kaiser R; Knops E; Heger E; Steger G; Klein F; Kurschat C; Di Cristanziano V
    Transpl Infect Dis; 2024 Feb; 26(1):e14233. PubMed ID: 38180168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Developments in the Management of Cytomegalovirus Infection After Transplantation.
    Meesing A; Razonable RR
    Drugs; 2018 Jul; 78(11):1085-1103. PubMed ID: 29961185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
    Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
    PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
    Bixby AL; Fitzgerald L; Park JM; Kaul D; Tischer S
    Transpl Infect Dis; 2021 Oct; 23(5):e13713. PubMed ID: 34428337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
    Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
    Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Associated With Genotypic Resistance and Outcome Among Solid Organ Transplant Recipients With Refractory Cytomegalovirus Infection.
    Tamzali Y; Pourcher V; Azoyan L; Ouali N; Barrou B; Conti F; Coutance G; Gay F; Tourret J; Boutolleau D
    Transpl Int; 2023; 36():11295. PubMed ID: 37398559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation.
    Lopau K; Greser A; Wanner C
    Clin Transplant; 2007; 21(1):80-5. PubMed ID: 17302595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation.
    Chen TT; David AP; Barthelmess EK; MacBrayne CE
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30608. PubMed ID: 37548491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
    Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Letermovir treatment for CMV infection in kidney and pancreas transplantation: A valuable option for complicated cases.
    Ortiz F; Lempinen M; Aaltonen S; Koivuviita N; Helanterä I
    Clin Transplant; 2022 Feb; 36(2):e14537. PubMed ID: 34797574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.
    Valencia Deray KG; Danziger-Isakov LA; Downes KJ
    J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S14-S21. PubMed ID: 38417084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM; Lake KD; Arenas JD; Fontana RJ
    Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.